Spyre Therapeutics (SYRE) Current Assets (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Current Assets data on file, last reported at $764.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 34.08% year-over-year to $764.0 million; the trailing twelve-month figure through Mar 2026 stood at $764.0 million (up 34.08% YoY), and the FY2025 full-year result was $777.8 million, up 27.82% from the prior year.
• Current Assets for Q1 2026 stood at $764.0 million, down from $777.8 million in the prior quarter.
• Across five years, Current Assets topped out at $777.8 million in Q4 2025 and bottomed at $44.4 million in Q1 2023.
• The 5-year median for Current Assets is $421.1 million (2024), against an average of $367.8 million.
• The widest annual swing landed in 2022, when Current Assets plunged 52.05%; it then jumped 998.08% in 2024.
• A 5-year view of Current Assets shows it stood at $62.3 million in 2022, then soared by 448.57% to $341.5 million in 2023, then surged by 78.16% to $608.5 million in 2024, then increased by 27.82% to $777.8 million in 2025, then decreased by 1.78% to $764.0 million in 2026.
• The last three Current Assets figures came in at $764.0 million (Q1 2026), $777.8 million (Q4 2025), and $504.6 million (Q3 2025), per Business Quant data.

Peer Comparison